The outcomes of the randomised placebo-controlled ACTIVATE trial were released in the New England Journal of Medicine and were carried out by a global team that included researchers from Massachusetts General Hospital. The majority of people who have pyruvate kinase deficiency experience potentially fatal complications such iron overload in the liver and/or heart, osteoporosis, gallbladder […]
